<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440189</url>
  </required_header>
  <id_info>
    <org_study_id>GIDOA-03</org_study_id>
    <nct_id>NCT04440189</nct_id>
  </id_info>
  <brief_title>Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Use of GID SVF-2 Device to Produce Autologous Adipose-Derived Stromal Vascular Fraction for Treatment of Osteoarthritis of the Knee: A Pivotal Medical Device Randomized Concurrent Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GID BIO, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GID BIO, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pivotal study to evaluate the efficacy and safety of a single injection of&#xD;
      autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of&#xD;
      pain with concomitant improvement in function associated with osteoarthritis of the knee&#xD;
      joint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, placebo controlled, parallel groups, double blind,&#xD;
      multi-center, interventional study of subjects with osteoarthritis of the knee. Subjects will&#xD;
      be randomized to receive an injection of LR (placebo) or SVF derived from their own adipose&#xD;
      tissue (experimental).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index</measure>
    <time_frame>6 months</time_frame>
    <description>The WOMAC is a self-administered questionnaire consisting of 14 items divided into 3 subscales, pain, stiffness and function. The primary efficacy will be achieved if the SVF dose group is shown to have a clinically meaningful improvement in pain and function at 6 months post-treatment, using the percent change in WOMAC score from baseline as the primary variable. The overall WOMAC score is normalized to a range of 0 to 100 points with a lower score indicating less symptoms of osteoarthritis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Summary of device, treatment and procedure related adverse event rates and severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive an injection of Lactated Ringers in their index knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stromal Vascular Fraction (SVF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an injection of Stromal Vascular Fraction in their index knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GID SVF-2 Device System</intervention_name>
    <description>The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Stromal Vascular Fraction (SVF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bilateral or unilateral knee osteoarthritis as diagnosed on pre-op MRI using the&#xD;
             Outerbridge Cartilage Classification as Grade II, Grade III, or Grade IV with full&#xD;
             thickness lesion of the articular cartilage is less than 1.5 cm in any direction&#xD;
&#xD;
          -  Index knee must present with a score ≥8 using the WOMAC pain scale (A1 subscale, 20&#xD;
             total points)&#xD;
&#xD;
          -  Study Subjects must be willing to voluntarily give written Informed Consent to&#xD;
             participate in the study and sign the Health Insurance Portability and Accountability&#xD;
             Act (HIPAA) authorization before any study procedures are performed&#xD;
&#xD;
          -  Males and females 35-85 years old&#xD;
&#xD;
          -  Subjects with BMI ≥22 and ≤ 37&#xD;
&#xD;
          -  Subjects must speak, read and understand English&#xD;
&#xD;
          -  Subjects must be able to return for multiple follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects whose knee pain is caused by:&#xD;
&#xD;
          -  unstable meniscal root tears or locked bucket handle meniscal tears&#xD;
&#xD;
          -  displaced meniscus tear&#xD;
&#xD;
          -  full thickness lesion of the articular cartilage greater than 1.5 cm in any direction&#xD;
&#xD;
          -  osteo chondritis dissecans&#xD;
&#xD;
          -  parameniscal, Baker's, or ganglion cysts&#xD;
&#xD;
          -  lipoma arborescens&#xD;
&#xD;
          -  Hoffa's Pad Syndrome&#xD;
&#xD;
          -  acute ligament tears&#xD;
&#xD;
          -  diffuse edema&#xD;
&#xD;
          -  pain due to patellar mal-tracking or patellar dislocations&#xD;
&#xD;
          -  Outerbridge Scale Grade I as diagnosed on MRI&#xD;
&#xD;
          -  Outerbridge Scale Grade IV where the full thickness lesion of the articular cartilage&#xD;
             is greater than 1.5 cm in any direction, as diagnosed on MRI&#xD;
&#xD;
          -  Subjects who have had surgery of either knee within 6 months prior to the surgery&#xD;
             visit&#xD;
&#xD;
          -  Subjects who have had a major injury to either knee within 12 months prior to the&#xD;
             surgery visit&#xD;
&#xD;
          -  Subjects who have had an injection in either knee in the prior 6 months, including&#xD;
             corticosteroids, viscosupplementation, stromal vascular fraction (SVF), bone marrow&#xD;
             stem cells, or platelet rich plasma&#xD;
&#xD;
          -  Subjects who have gout, rheumatoid arthritis, lupus arthropathy, psoriatic arthritis,&#xD;
             avascular necrosis, severe bone deformity, infection of the knee joint, fibromyalgia,&#xD;
             pes anserine bursitis, or neurogenic or vascular claudication&#xD;
&#xD;
          -  Subjects that are unwilling to stop taking prescription or over the counter pain&#xD;
             medication 7 days prior to any visit&#xD;
&#xD;
          -  Subjects that are allergic to lidocaine, epinephrine or valium&#xD;
&#xD;
          -  Subjects with a history of bleeding disorders, anticoagulation therapy that cannot be&#xD;
             stopped as follows prior to injection; thrombolytics and anti-platelet medication&#xD;
             including but not limited to Coumadin (warfarin) for 3 days, Plavix (colpidogrel) for&#xD;
             3 days, ASA/NSAIDs/fish oil supplements for 7 days, Xeralta® (rivaroxaban) for 24&#xD;
             hours&#xD;
&#xD;
          -  Subjects with systemic immunosuppressant use within 6 weeks from screening and&#xD;
             subjects with HIV or viral hepatitis&#xD;
&#xD;
          -  Subjects with chondrocalcinosis, Paget's disease or Villonodular synovitis&#xD;
&#xD;
          -  Subjects that use any form of tobacco, including e-cigarettes, more than once a week&#xD;
             over the most recent 1 year period&#xD;
&#xD;
          -  Women that are pregnant or planning to become pregnant during the study&#xD;
&#xD;
          -  Subjects on long term use of oral steroids&#xD;
&#xD;
          -  History of any chemotherapy or radiation therapy on either leg or adipose harvest site&#xD;
&#xD;
          -  Subjects currently on worker's compensation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Cimino, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>GID BIO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abigail Holewinski, MS, RD</last_name>
    <phone>6363992070</phone>
    <email>a.holewinski@gidbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashleigh Wodushek, MS</last_name>
    <phone>3039139051</phone>
    <email>a.wodushek@gidbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Anthonisen</last_name>
      <phone>916-734-4307</phone>
      <email>canthonisen@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erica Goude</last_name>
      <phone>9167340384</phone>
      <email>emgoude@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charles DeMesa, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alyssa Speciale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Mullins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandee Waite, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Panero, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shrock Orthopaedic Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Callegari</last_name>
      <phone>504-988-0200</phone>
      <email>ctu@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime R Garza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Regenerative Institute</name>
      <address>
        <city>Cedar Knolls</city>
        <state>New Jersey</state>
        <zip>07927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalaka Paranjpe</last_name>
      <phone>973-998-8301</phone>
      <email>sparanjpe@kesslerfoundation.org</email>
    </contact>
    <investigator>
      <last_name>Gerald Malanga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina Research Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caleb Michalek, CCRC</last_name>
      <phone>704-323-3698</phone>
      <email>caleb.michalek@orthocarolina.com</email>
    </contact>
    <contact_backup>
      <last_name>Taylor Rowe</last_name>
      <phone>704-323-2261</phone>
      <email>taylor.rowe@orthocarolina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Claude T Moorman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Salzman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Matthews, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Carstens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Hartzell</last_name>
      <phone>336-713-3824</phone>
      <email>ehartzel@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nina Cruz-Diaz</last_name>
      <phone>336.716.0824</phone>
      <email>nmcruzdi@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neil Sparks, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Katz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Waterman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Coates, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxwell Langfitt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Miles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heath Thornton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Linter, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Center for Cell Therapy and Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Krieger</last_name>
      <phone>210-616-0301</phone>
      <email>jkrieger@txps.net</email>
    </contact>
    <investigator>
      <last_name>Jaime R Garza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Garza JR, Campbell RE, Tjoumakaris FP, Freedman KB, Miller LS, Santa Maria D, Tucker BS. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. Am J Sports Med. 2020 Mar;48(3):588-598. doi: 10.1177/0363546519899923.</citation>
    <PMID>32109160</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

